City of Hope | Strategic Alliance Partners

A blood cancer specialist discusses how the development of tyrosine kinase inhibitors in the 1990s to treat chronic myelogenous leukemia drove major oncology advancements over the next three decades.

When cancer treatments stop working, it is not the end of the line. Most patients with advanced disease will be on continuous therapy, and that means trying different options along the way.